1. Increased Bioavailability of 11-Keto-β-Boswellic Acid Following Single Oral Dose Frankincense Extract Administration After a Standardized Meal in Healthy Male Volunteers: Modeling and Simulation Considerations for Evaluating Drug Exposures. Skarke C., Kuczka K., Tausch L., Werz O., Rossmanith T, Jeffrey S. Barrett J.S., Harder S., Holtmeier W., and Schwarz, JA.. J Clin Pharmacol 0091270011422811 , first published on December 13, 2011 as doi:10.1177/0091270011422811

2. Platelet activation markers after conversion from azathioprine to sirolimus based immunosuppression in renal transplant recipients. Graff J, Harder S, Reiche C, Scheuermann EH, Gossmann J.Int J Clin Pharmacol Ther. 2012 Dec;50(12):873-9. doi: 10.5414/CP201768.

3. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Harder, S, Graff, J. Eur J Clin Pharmacol. 2013 Apr 26. [Epub ahead of print]

4. Anticoagulant therapy with the oral direct factor xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Graff J., Harder, S. Clin Pharmacokinetic. 2013 Apr;52(4):243-54. doi: 10.1007/s40262-013-0034-0

5. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Martinez-Saguer I, Cicardi M, Suffritti C, Rusicke E, Aygören-Pürsün E, Stoll H, Rossmanith T, Feussner A, Kalina U, Kreuz W.Transfusion. 2013 Nov 24. doi: 10.1111/trf.12501. [Epub ahead of print]